DIAMOND THERAPEUTICS
LIVE

Serial Number

97229628

Owner

Diamond Therapeutics Inc.

Attorney

Gary P. Oakeson

Filing Date

Jan 20, 2022

Add to watchlist:

No watchlists yet
View on USPTO

DIAMOND THERAPEUTICS Trademark

Serial Number: 97229628

DIAMOND THERAPEUTICS is a trademark filed by Diamond Therapeutics Inc. on January 20, 2022. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 39 (Transportation & Storage), Class 40 (Treatment & Processing), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Diamond Therapeutics Inc. (2 trademarks)

36 Toronto Street, Suite 1170
Toronto M5C2C5 , CA

Entity Type: 03

Trademark Details

Filing Date

January 20, 2022

Registration Date

Not Registered

Goods & Services

Education services, namely providing computer training for brain and neural activity, providing information regarding psychiatric therapies and pharmacology in the field of psychedelic-based mental health treatments for humans

Wholesale distributorship featuring psychedelic-based pharmaceuticals, drugs, therapeutic pharmaceuticals, and health care products used to improve, treat, and prevent diseases, disorders, conditions, and ailments in humans; developing marketing strategies for others in the field of psychedelic-based pharmaceuticals, drugs, and health care products used to improve, treat and prevent diseases, disorders, conditions, and ailments in humans; wholesale distributorship featuring distribution and sale of psychedelic-based pharmaceuticals, drugs, therapeutic pharmaceuticals, and health care products used to treat mental conditions, illnesses, and disorders in humans; developing marketing strategies for others in the field of psychedelic-based pharmaceuticals, drugs, therapeutic pharmaceuticals, and health care products used to treat mental conditions, illnesses, and disorders in humans

Licensing of proprietary information in the field of psychedelic-based pharmaceuticals, drugs, therapies, and health care products used to improve, treat, and prevent mental health diseases, disorders, conditions, illnesses, and ailments

Electroencephalogram (EEG) devices namely electroencephalography (EEG) device comprising a sensor for monitoring and measuring brain and neural activity for medical diagnostic purposes during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; medical devices for monitoring, sensing, measuring, and training brain and neural activity; medical devices in the nature of elecroencephalogram (EEG), electrocardiogram (EKG), magnetoencephalogram (MEG), functional near-infrared spectroscopy (fNRIS), positron emission tomography (PET), transcranial functional ultrasound, imaging devices, pupillometers, voltmeters, photodiodes, complementary metal-oxide semiconductor (CMOS), ultrasound, piezoelectric resonant devices, lead zirconate titanate (PZT), capacitive micromachined ultrasonic transducer (CMUT), micromembrane ultrasound transducer (PMUT), auditory stimulating devices, visual stimulating devices, sleep monitoring devices, thermometers, heart monitors, blood pressure monitors for use in therapy of cognitive states to monitor, sense, or measure cognitive impairment during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; medical devices for stimulating nerves during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; medical device used for treating of mental health disorders noninvasively, namely, nodes, headsets, eyewear, probes, computers, tablets, hand-held, mobile and smart phones, smart watches, wrist monitors, body monitors, including implants, body bands, rings and sleeves, fitness trackers for monitoring, sensing, stimulating, measuring, and training brain and neural activity during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; tamper resistant dosage dispensers for administering psychedelic-based medicine to human patients

Warehousing services, namely, distribution of psychedelic-based pharmaceuticals, pharmaceutical drugs, therapeutic pharmaceuticals, and health care products, namely, central nervous system health care products used to improve, treat, and prevent diseases, disorders, conditions, and ailments in humans; Distribution services, namely, delivery of psychedelic-based pharmaceuticals, pharmaceutical drugs, therapeutic pharmaceuticals, and health care products, namely, central nervous pharmaceuticals, pharmaceutical drugs, therapeutic pharmaceuticals, and health care products, namely, central nervous system health care products used to improve, treat, and prevent diseases, disorders, conditions, and ailments in humans

Downloadable computer applications for monitoring, sensing, stimulating, measuring, and training brain and neural activity during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; downloadable computer applications for use in therapy of cognitive states during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; downloadable computer software applications for monitoring, sensing, stimulating, measuring, and training brain and neural activity during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; downloadable computer software applications for use in therapy of cognitive states during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; medical systems comprising software and/or hardware for monitoring, sensing, stimulating, measuring, and training brain and neural activity during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; medical systems comprising software and/or hardware for use in therapy of cognitive states during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; downloadable software as a Medical Device (SaMD) for monitoring, sensing, stimulating, measuring, and training brain and neural activity during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; downloadable software as a Medical Device (SaMD) for use in therapy of cognitive states during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans; downloadable software as a Medical Device (SaMD) for stimulating nerves during use of psychedelic-based pharmaceuticals, pharmaceutical preparations and products in humans

Psychedelic-based pharmaceuticals, pharmaceutical preparations and products for the treatment of central nervous system conditions, illnesses, and disorders in humans; psychedelic-based medicines for the treatment of central nervous system conditions, illnesses, and disorders; neurogenerative psychedelic-based pharmaceutical drugs for use in humans; serotonin receptor agonists and antagonist pharmaceutical drugs for use in humans; abuse deterrent products, namely, very low-dose, low dose, and extended release psychedelic-based pharmaceutical preparations to avoid overdosing or diversion of psychedelic drugs; psychedelic-based pharmaceutical preparations for managing a mental, a behavioral, or a neuropsychiatric condition, or its symptoms, namely, motivation, attention, accuracy, response speed, perseverance, cognitive engagement, executive function, mood, behavior; therapeutics for the treatment of mental conditions, illnesses, and disorders in humans

Custom manufacture for others of psychedelic-based pharmaceuticals, pharmaceutical drugs, therapeutic pharmaceuticals, and health care products namely, central nervous system health care products used to improve, treat, and prevent mental health diseases, disorders, conditions, and ailments in humans; Custom manufacture for others of psychedelic-based pharmaceuticals, drugs, therapeutic pharmaceuticals, and health care products used to treat mental conditions, illnesses, and disorders in humans

Psychedelic-based pharmaceutical research and development for humans; psychedelic-based pharmaceutical drug development for humans; psychedelic-based pharmaceutical research and development in the field of mental health treatments for humans; psychedelic-based drug discovery services for humans; consultancy pertaining to pharmacology in the field of psychedelic-based mental health treatments in humans; psychedelic-based medical research in the field of human mental health conditions, illnesses, and disorders; neuropsychiatric drug discovery services including pre-clinical and clinical pharmaceutical psychedelic-based drug development for humans; psychedelic-based pharmaceutical drug development and discovery including new chemical entities, neurogenerative drugs, serotonin receptor agonists and antagonist, abuse deterrent drugs, and pharmaceutical preparations for managing a mental, a behavioral, or a neuropsychiatric condition, or its symptoms in humans

Filing History

NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
May 2, 2026 GNS2
INQUIRY TO SUSPENSION E-MAILED
May 2, 2026 GNSI
SUSPENSION INQUIRY WRITTEN
May 2, 2026 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 12, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 12, 2025 GNSL
SUSPENSION LETTER WRITTEN
Aug 12, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 23, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 23, 2025 CRFA
ASSIGNED TO LIE
Jul 23, 2025 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jul 18, 2025 ERSI
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Apr 21, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Apr 21, 2025 XELR
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 19, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 19, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 19, 2025 CNSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Apr 10, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Apr 10, 2024 GNSL
SUSPENSION LETTER WRITTEN
Apr 10, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 1, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 1, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 1, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jan 16, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jan 16, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 16, 2023 GNRN
NON-FINAL ACTION E-MAILED
Oct 16, 2023 GNRT
NON-FINAL ACTION WRITTEN
Oct 16, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 22, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 21, 2023 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Sep 21, 2023 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 8, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 8, 2023 GNSL
SUSPENSION LETTER WRITTEN
Jun 8, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 13, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 12, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 12, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 12, 2022 GNRN
NON-FINAL ACTION E-MAILED
Nov 12, 2022 GNRT
NON-FINAL ACTION WRITTEN
Nov 12, 2022 CNRT
ASSIGNED TO EXAMINER
Oct 29, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 25, 2022 NWOS
NEW APPLICATION ENTERED
Jan 24, 2022 NWAP